Figure 5.

Competitive inhibition of ¹²⁵I-CD4 binding to gp120. A fixed concentration of ¹²⁵I-labeled soluble recombinant CD4 (50 nM) was added to immobilized rgp160 (solid bars, MN; hatched bars, LAV isolate-derived) in the absence or presence of 10-fold molar excess (0.5 μM) of unlabeled TSP1, TSP1-derived peptides CSVTCG or GRGDS, scrambled control peptide VGSCCT, fusion proteins containing the TSP1-binding domain of CD36 (CFP, aa 67–157) or LIMPII (aa 75–155), downstream fusion protein LFP156–243, or an equal volume of saliva (final twofold dilution). Samples were incubated and bound TSP1 was measured as in Fig. 2. Shown is a single data set of triplicate samples. (n = 3, error as SD).